Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer
Metastatic Cancer

First Posted Date: 2005-02-08

Last Posted Date: 2013-06-20

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00103298

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer

Phase 2

Terminated

Conditions: Gastric Cancer

First Posted Date: 2005-02-08

Last Posted Date: 2010-10-13

Lead Sponsor: California Cancer Consortium

Registration Number: NCT00103103

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
City of Hope Medical Group, Pasadena, California, United States
🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States

and more 2 locations

Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer

Phase 2

Completed

Conditions: Signet Ring Adenocarcinoma of the Colon
Mucinous Adenocarcinoma of the Colon
Stage IV Rectal Cancer
Recurrent Colon Cancer
Adenocarcinoma of the Rectum
Recurrent Rectal Cancer
Stage IV Colon Cancer

Interventions: Biological: cetuximab
Biological: bevacizumab
Drug: oxaliplatin
Drug: leucovorin calcium
Drug: fluorouracil

First Posted Date: 2005-01-07

Last Posted Date: 2015-07-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 66

Registration Number: NCT00100841

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

First Posted Date: 2004-12-09

Last Posted Date: 2013-06-12

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 16

Registration Number: NCT00098982

Locations: 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇬🇧
Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
🇮🇹
Istituto Nazionale per lo Studio e la Cura dei Tumori, Naples, Italy

Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Biological: bevacizumab
Drug: irinotecan hydrochloride
Drug: fluorouracil
Drug: leucovorin calcium
Drug: Oxaliplatin

First Posted Date: 2004-12-09

Last Posted Date: 2023-07-05

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 247

Registration Number: NCT00098787

Locations: 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸
St. Mary - Corwin Regional Medical Center, Pueblo, Colorado, United States
🇺🇸
Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States

and more 107 locations

Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)

Phase 3

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: carboplatin
Drug: cisplatin
Drug: docetaxel
Drug: fluorouracil

First Posted Date: 2004-11-09

Last Posted Date: 2013-11-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 145

Registration Number: NCT00095875

Locations: 🇺🇸
Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
🇺🇸
Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸
Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - Main Campus, Boca Raton, Florida, United States

and more 12 locations

Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer

Phase 3

Completed

Conditions: Colon Adenocarcinoma
Stage IIA Colon Cancer AJCC v7
Stage IIB Colon Cancer AJCC v7
Stage IIC Colon Cancer AJCC v7
Stage IIIC Colon Cancer AJCC v7
Stage IIIA Colon Cancer AJCC v7
Stage IIIB Colon Cancer AJCC v7

Interventions: Biological: Bevacizumab
Drug: Leucovorin Calcium
Drug: Fluorouracil
Drug: Oxaliplatin

First Posted Date: 2004-11-09

Last Posted Date: 2019-07-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2710

Registration Number: NCT00096278

Locations: 🇺🇸
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, Pennsylvania, United States

Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Pancreas
Stage II Pancreatic Cancer
Stage III Pancreatic Cancer

Interventions: Radiation: radiation therapy
Drug: oxaliplatin
Drug: fluorouracil
Drug: gemcitabine hydrochloride

First Posted Date: 2004-11-09

Last Posted Date: 2013-07-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00096070

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

Fluorouracil, Cisplatin, and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Nasopharyngeal Cancer

Phase 2

Conditions: Head and Neck Cancer

First Posted Date: 2004-10-08

Last Posted Date: 2013-05-15

Lead Sponsor: Aichi Cancer Center

Target Recruit Count: 90

Registration Number: NCT00093665

Locations: 🇯🇵
Kanazawa University, Kanazawa, Japan
🇯🇵
Nara Medical University Cancer Center, Nara, Japan
🇯🇵
Graduate School of Medical Science at the University of Ryukyu, Okinawa, Japan

and more 4 locations

Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: Bleomycin Sulfate
Biological: Filgrastim
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Cisplatin
Drug: Doxorubicin Hydrochloride (DOX)
Drug: Fluorouracil
Drug: Leucovorin calcium
Drug: Etoposide
Drug: Pentamidine
Drug: Prednisone
Drug: Ifosfamide
Drug: Trimethoprim-Sulfamethoxazole
Drug: Methotrexate
Drug: Vincristine Sulfate
Drug: Methylprednisolone
Drug: Zidovudine (AZT)
Radiation: Radiation Therapy

First Posted Date: 2004-10-05

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 46

Registration Number: NCT00002524

Locations: 🇺🇸
MD Anderson Cancer Center Orlando, Orlando, Florida, United States
🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy